Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM26YJ1)

Drug Name

PEGPH20 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Pancreatic cancer	2C10	Phase 2	[2]
Gallbladder disease	DC11.3	Phase 1	[1]
Gastric adenocarcinoma	2B72	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hyaluronidase (HYAL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Asenapine	DMSQZE2	Schizophrenia	6A20	Approved	[4]
Hyqvia	DM0RXF5	Immunodeficiency	4A00-4A85	Approved	[5]
PEGylated hyaluronidase (human recombinant)	DM1D6BT	Pancreatic cancer	2C10	Phase 1/2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.